Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.

Rapid onset opioids for the optimized treatment of breakthrough cancer pain

24 Jul 2018
Cancer is hard enough as it is – unnecessarily increasing the treatment does not help patients, doctors or the practice of healthcare in general.
At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.